APEX pivotal trial results for bezuclastinib in AdvSM show a 65% objective response rate (CR+CRh+PR+CI) by mIWG criteria and 81% ORR by PPR criteria, alongside a well-tolerated safety profile. The strong efficacy readout is a meaningful positive catalyst for clinical development and potential regulatory positioning for AdvSM.
APEX pivotal trial results for bezuclastinib in AdvSM show a 65% objective response rate (CR+CRh+PR+CI) by mIWG criteria and 81% ORR by PPR criteria, alongside a well-tolerated safety profile. The strong efficacy readout is a meaningful positive catalyst for clinical development and potential regulatory positioning for AdvSM.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
